A - Human Necessities – 61 – K
Patent
A - Human Necessities
61
K
167/207
A61K 31/00 (2006.01) A61K 31/275 (2006.01) A61K 31/44 (2006.01) A61K 31/495 (2006.01) A61K 31/505 (2006.01) A61K 31/55 (2006.01) A61K 31/66 (2006.01)
Patent
CA 2004616
ABSTRACT OF THE DISCLOSURE THERAPEUTIC USE OF CALCIUM ENTRY BLOCKERS IN RETINAL OR OPTIC NERVE DYSFUNCTION Ischemia or edema of the retina or optic nerve results in retinal dysfunction. This retinal dysfunction can be associated with the activation of calcium channels and/or excitatory amino acid receptors. The prophylactic or therapeutic administration of compounds to block these processes can ameliorate or prevent retinal dysfunction. These compounds include the classes of calcium channel antagonists. Therapeutic treatment with compounds include dihydropyridines and diphenylpiperazines as calcium channel antagonists. Such compounds also exhibit a prophylactic effect to ischemia and edema of the retina or optic nerve. Rat models are provided for screening compounds capable of ameliorating retinal dysfunction. Particularly, calcium entry blockers and excitatory amino acid antagonists can be screened and the host eyes examined for the effect of the drugs. The model animal is a rat having a salt-inducible retinal dysfunction and/or a retinal dysfunction as a result of vascular occlusion resulting in ischemia.
Crosson Craig E.
Potter David E.
Borden Ladner Gervais Llp
Crosson Craig E.
Houston Biotechnology Incorporated
Potter David E.
LandOfFree
Therapeutic use of calcium entry blockers in retinal or... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Therapeutic use of calcium entry blockers in retinal or..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Therapeutic use of calcium entry blockers in retinal or... will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1911020